ATE328000T1 - Phospholipidester von clofarabin - Google Patents
Phospholipidester von clofarabinInfo
- Publication number
- ATE328000T1 ATE328000T1 AT04721537T AT04721537T ATE328000T1 AT E328000 T1 ATE328000 T1 AT E328000T1 AT 04721537 T AT04721537 T AT 04721537T AT 04721537 T AT04721537 T AT 04721537T AT E328000 T1 ATE328000 T1 AT E328000T1
- Authority
- AT
- Austria
- Prior art keywords
- phospholipide
- clofarabine
- esters
- lipidesters
- tumors
- Prior art date
Links
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 title 1
- 229960000928 clofarabine Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45600303P | 2003-03-19 | 2003-03-19 | |
| EP03006059A EP1460082A1 (en) | 2003-03-19 | 2003-03-19 | Phospholipid esters of clofarabine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE328000T1 true ATE328000T1 (de) | 2006-06-15 |
Family
ID=33031244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04721537T ATE328000T1 (de) | 2003-03-19 | 2004-03-18 | Phospholipidester von clofarabin |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7419965B2 (enExample) |
| EP (2) | EP1460082A1 (enExample) |
| JP (1) | JP2006520359A (enExample) |
| KR (1) | KR20050109939A (enExample) |
| CN (1) | CN100369926C (enExample) |
| AT (1) | ATE328000T1 (enExample) |
| AU (1) | AU2004222163A1 (enExample) |
| CA (1) | CA2519434A1 (enExample) |
| CY (1) | CY1105572T1 (enExample) |
| DE (1) | DE602004001047T2 (enExample) |
| DK (1) | DK1606233T3 (enExample) |
| ES (1) | ES2265636T3 (enExample) |
| MX (1) | MXPA05008817A (enExample) |
| NO (1) | NO20053903L (enExample) |
| NZ (1) | NZ542011A (enExample) |
| PL (1) | PL1606233T3 (enExample) |
| PT (1) | PT1606233E (enExample) |
| RU (1) | RU2347786C2 (enExample) |
| SI (1) | SI1606233T1 (enExample) |
| WO (1) | WO2004083155A2 (enExample) |
| ZA (1) | ZA200507541B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2070938A1 (en) | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
| CN102079766A (zh) * | 2009-11-29 | 2011-06-01 | 海南中化联合制药工业股份有限公司 | 一种单磷酸阿糖腺苷的制备方法 |
| CN101709073B (zh) * | 2009-12-01 | 2013-01-23 | 北京大学 | 核苷酸磷脂分子及脂质体及其制备方法和应用 |
| CN103232510B (zh) * | 2012-11-23 | 2015-12-23 | 北京大学 | 5’-氨基-2’,5’-双脱氧核苷酸磷脂分子及其制备方法和应用 |
| US9771385B2 (en) * | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| KR102371969B1 (ko) | 2016-12-23 | 2022-03-08 | 주식회사 엘지에너지솔루션 | 배터리 모듈 |
| US12397058B2 (en) | 2018-06-26 | 2025-08-26 | Tsrl, Inc. | Metabolically stable prodrugs |
| WO2024059754A1 (en) * | 2022-09-14 | 2024-03-21 | Quantapore, Inc. | Polythiolated linkers for stable nanoparticle suspensions and uses thereof |
| WO2025096481A1 (en) * | 2023-10-29 | 2025-05-08 | Maia Biotechnology, Inc. | Telomere-targeting phosphatidyl-thio conjugates |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4751221A (en) * | 1985-10-18 | 1988-06-14 | Sloan-Kettering Institute For Cancer Research | 2-fluoro-arabinofuranosyl purine nucleosides |
| JPS6383094A (ja) * | 1986-09-27 | 1988-04-13 | Toyo Jozo Co Ltd | エ−テル型ヌクレオシド−リン脂質複合体 |
| DE4026265A1 (de) | 1990-08-20 | 1992-02-27 | Boehringer Mannheim Gmbh | Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel |
| US5512671A (en) * | 1993-02-16 | 1996-04-30 | Wake Forest University | Ether lipid-nucleoside covalent conjugates |
| DE4321978A1 (de) * | 1993-07-01 | 1995-01-12 | Boehringer Mannheim Gmbh | Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel |
| DK0791056T3 (da) * | 1994-11-12 | 2005-07-04 | Heidelberg Pharma Gmbh | Lipidopspaltende enzymkompleks |
| US7517858B1 (en) * | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
| US6670341B1 (en) * | 1999-10-28 | 2003-12-30 | Wake Forest University Health Sciences | Compositions and methods for double-targeting virus infections and targeting cancer cells |
| US7026469B2 (en) * | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
-
2003
- 2003-03-19 EP EP03006059A patent/EP1460082A1/en not_active Withdrawn
-
2004
- 2004-03-18 AT AT04721537T patent/ATE328000T1/de not_active IP Right Cessation
- 2004-03-18 ES ES04721537T patent/ES2265636T3/es not_active Expired - Lifetime
- 2004-03-18 NZ NZ542011A patent/NZ542011A/en unknown
- 2004-03-18 US US10/549,799 patent/US7419965B2/en not_active Expired - Fee Related
- 2004-03-18 SI SI200430052T patent/SI1606233T1/sl unknown
- 2004-03-18 DE DE602004001047T patent/DE602004001047T2/de not_active Expired - Lifetime
- 2004-03-18 JP JP2006504723A patent/JP2006520359A/ja active Pending
- 2004-03-18 CN CNB2004800073933A patent/CN100369926C/zh not_active Expired - Fee Related
- 2004-03-18 AU AU2004222163A patent/AU2004222163A1/en not_active Abandoned
- 2004-03-18 PL PL04721537T patent/PL1606233T3/pl unknown
- 2004-03-18 RU RU2005130992/04A patent/RU2347786C2/ru not_active IP Right Cessation
- 2004-03-18 CA CA002519434A patent/CA2519434A1/en not_active Abandoned
- 2004-03-18 DK DK04721537T patent/DK1606233T3/da active
- 2004-03-18 KR KR1020057014672A patent/KR20050109939A/ko not_active Abandoned
- 2004-03-18 MX MXPA05008817A patent/MXPA05008817A/es active IP Right Grant
- 2004-03-18 PT PT04721537T patent/PT1606233E/pt unknown
- 2004-03-18 WO PCT/EP2004/002810 patent/WO2004083155A2/en not_active Ceased
- 2004-03-18 EP EP04721537A patent/EP1606233B1/en not_active Expired - Lifetime
-
2005
- 2005-08-22 NO NO20053903A patent/NO20053903L/no not_active Application Discontinuation
- 2005-09-16 ZA ZA200507541A patent/ZA200507541B/en unknown
-
2006
- 2006-08-07 CY CY20061101101T patent/CY1105572T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1460082A1 (en) | 2004-09-22 |
| US7419965B2 (en) | 2008-09-02 |
| MXPA05008817A (es) | 2005-10-18 |
| CN100369926C (zh) | 2008-02-20 |
| PL1606233T3 (pl) | 2006-10-31 |
| NO20053903D0 (no) | 2005-08-22 |
| WO2004083155A2 (en) | 2004-09-30 |
| ES2265636T3 (es) | 2007-02-16 |
| NO20053903L (no) | 2005-12-19 |
| CA2519434A1 (en) | 2004-09-30 |
| KR20050109939A (ko) | 2005-11-22 |
| DK1606233T3 (da) | 2006-09-18 |
| EP1606233B1 (en) | 2006-05-31 |
| DE602004001047D1 (de) | 2006-07-06 |
| JP2006520359A (ja) | 2006-09-07 |
| DE602004001047T2 (de) | 2007-04-19 |
| RU2005130992A (ru) | 2006-04-10 |
| CN1771253A (zh) | 2006-05-10 |
| PT1606233E (pt) | 2006-09-29 |
| SI1606233T1 (sl) | 2006-10-31 |
| ZA200507541B (en) | 2006-05-31 |
| RU2347786C2 (ru) | 2009-02-27 |
| CY1105572T1 (el) | 2010-07-28 |
| AU2004222163A1 (en) | 2004-09-30 |
| US20060293514A1 (en) | 2006-12-28 |
| WO2004083155A3 (en) | 2005-03-31 |
| NZ542011A (en) | 2008-02-29 |
| EP1606233A2 (en) | 2005-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
| BR0315689A (pt) | Alvo para terapia de dano cognitivo | |
| CY1115059T1 (el) | Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα | |
| DE60329274D1 (de) | Kontrastmittel und verfahren zum imaging von naaldase oder psma | |
| ATE453653T1 (de) | Platinkomplexe zur behandlung von tumoren | |
| DK1503788T3 (da) | Behandling af alpha-galactosidase A-deficiens | |
| DE60328476D1 (de) | Medizinisches ballonsystem zur behandlung von adipositas | |
| DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
| DE60233955D1 (de) | Spezifische bindungsmittel von human angiopoietin-2 | |
| DE60325770D1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
| DE50306850D1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| SE0302304D0 (sv) | Novel compounds | |
| ATE328000T1 (de) | Phospholipidester von clofarabin | |
| CY1110043T1 (el) | 2-αμινοβενζουλ παραγωγα | |
| CY1107562T1 (el) | Χρηση των ν-(2-αρυλ-προπιονυλ)-σουκλφοναμιδιων για τη θepαπεια του τραυματος του νωτιαιου μυελου | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| DE60325194D1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
| ATE504297T1 (de) | Visnadin zur behandlung von kopfhautjucken | |
| NO20052814D0 (no) | Cytomodulerende peptider for behandling av interstitielle cystitt | |
| DE602005013650D1 (de) | Proteinhydrolysat zur behandlung von müdigkeit | |
| DE50212649D1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1606233 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |